Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Biophytis ( (BPTSY) ) just unveiled an announcement.
On January 28, 2026, Biophytis announced it had signed a landmark agreement to create a Hong Kong-based joint venture, Biophytis Biopharmaceutical Holding LTD, with a consortium of Asian partners led by China’s Ronghui Renhe Life Technology, to develop and commercialize its sarcopenia drug candidate BIO101 in China, South Korea and Japan. Under the deal, Biophytis will contribute its intellectual property in these territories, while the Asian partners will provide up to $20 million in financing over three years, including $10 million in the first year and an initial $3 million upon the JV’s creation, giving Biophytis and its founders a 29% stake and the partners 71%, with a five-member board dominated by Biophytis representatives. The joint venture is scheduled to be set up within 180 days and to become operational in the first half of 2026, enabling launch in the second half of 2026 of SARA-31, a 942-patient international Phase 3 trial designed to support conditional marketing authorizations for BIO101 in sarcopenia in Asia and Europe, with most patients in China and Japan and 200 in Europe under Biophytis’ direct coordination. The transaction strengthens Biophytis’ strategic positioning in high-growth Asian markets for age-related muscle loss, secures non-dilutive funding for its pivotal program, and underscores external validation of BIO101’s potential in a field with no approved treatments and significant unmet medical need among older populations.
The most recent analyst rating on (BPTSY) stock is a Hold with a $0.65 price target. To see the full list of analyst forecasts on Biophytis stock, see the BPTSY Stock Forecast page.
Spark’s Take on BPTSY Stock
According to Spark, TipRanks’ AI Analyst, BPTSY is a Neutral.
The score is primarily held down by weak financial performance (no revenue, ongoing cash burn, and negative equity), reinforced by bearish technicals with the stock trading below major moving averages. Valuation is also constrained by negative earnings and no dividend support, with only a minor offset from oversold momentum readings.
To see Spark’s full report on BPTSY stock, click here.
More about Biophytis
Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age-related diseases, notably muscular disorders such as sarcopenia and metabolic conditions like obesity. Its lead small-molecule candidate, BIO101 (20-hydroxyecdysone), is Phase 3–ready in sarcopenia and Phase 2–ready in obesity, supported by what the company describes as the world’s most advanced clinical program in age-related sarcopenia. Headquartered in Paris with subsidiaries in Cambridge, Massachusetts, and Brazil, Biophytis is listed on Euronext Growth Paris and has American Depositary Shares trading on the OTC market.
Average Trading Volume: 772
Technical Sentiment Signal: Sell
Current Market Cap: $3.03M
See more data about BPTSY stock on TipRanks’ Stock Analysis page.